Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Waldenström Macroglobulinemia: A Systematic Review and Meta-analysis
- 1 October 2020
- journal article
- review article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 20 (10), e694-e711
- https://doi.org/10.1016/j.clml.2020.05.021
Abstract
No abstract availableThis publication has 52 references indexed in Scilit:
- Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large National Private Claims DatabaseBone Marrow Transplantation, 2012
- Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysisBlood, 2011
- The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applicationsBlood, 2011
- Prognostic value of the International Scoring System and response in patients with advanced Waldenstrom macroglobulinemiaHaematologica, 2011
- Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenstrom's macroglobulinemia. Results of a retrospective analysis of the Societe Francaise de Greffe de Moelle et de Therapie CellulaireHaematologica, 2010
- Autologous Stem Cell Transplantation as Part of First-Line Treatment of Waldenström’s MacroglobulinemiaTransplantation and Cellular Therapy, 2007
- Measuring inconsistency in meta-analysesBMJ, 2003
- Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003
- Allogeneic bone marrow transplantation for advanced Waldenstrom’s macroglobulinemiaBone Marrow Transplantation, 1999
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986